Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
Abasaglar® (insulin glargine): Intravenous Use
Abasaglar is administered subcutaneously and should not be administered intravenously.
After injection of Abasaglar into the SC tissue, the acidic solution is neutralized, leading to formulation of micro-precipitates from which small amounts of Abasaglar are continuously released.1
Abasaglar has a slow and prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak.2
Special Warnings And Precautions For Use
Abasaglar is not the insulin of choice for the treatment of DKA. Instead, regular insulin administered intravenously is recommended in such cases.1
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL
DKA = diabetic ketoacidosis
SC = subcutaneous
Date of Last Review: April 02, 2019